Is Curex legit? An honest look
A straight account of what Curex is, whether the treatment is real medicine, and the specific things worth knowing before you sign up — including the unflattering ones.
Curex is a real US telehealth company (founded 2019, based in New York) that provides at-home sublingual immunotherapy for environmental allergies — a legitimate, evidence-based treatment delivered by licensed clinicians. As with any young direct-to-consumer health brand, there are specific things worth knowing before you sign up, and this page lays them out plainly rather than selling.
Medically reviewed by Dr. Chet Tharpe, M.D. · Last reviewed August 2026
The basics
What Curex actually is
Curex is an online allergy and asthma clinic. It offers at-home allergen testing, review and prescribing by licensed clinicians, and mailed sublingual immunotherapy — allergy drops taken under the tongue daily at home — for environmental allergies like pollen, dust mites, and pet dander. The treatment approach, sublingual immunotherapy, is a recognized form of allergen immunotherapy — the only category of allergy treatment that modifies the underlying allergy rather than just masking symptoms.
The evidence
Is the treatment real medicine?
Yes. A Cochrane review of 60 randomized, placebo-controlled trials found sublingual immunotherapy reduced allergic-rhinitis symptoms and medication use versus placebo. A 2026 real-world study of 2,897 patients on telemedicine-delivered sublingual immunotherapy reported symptom improvement rising over time (from 28% at 12 months to 45% at 24 months), adherence above 90%, and no cases of anaphylaxis. That real-world study is observational, so it shows patients improved and stayed on treatment rather than proving the online model beats in-person care.
Straight talk
The concerns worth knowing
- Custom drops are off-label. The allergen extracts are FDA-regulated, but a personalized multi-allergen mixture isn’t a fixed FDA-approved product, so it’s prescribed off-label. That’s legal and common — but it also means the FDA hasn’t evaluated that specific mixture. Only single-source sublingual tablets (grass, ragweed, dust mite) are FDA-approved.
- There was a 2025 FDA warning letter — about GLP-1 marketing, not allergy. Because it is the question people most often arrive with, the full account is directly below.
- Direct-to-consumer basics. The New York telehealth entity is not BBB accredited and carries a BBB rating of C. Read recent customer reviews and understand the subscription, billing, and cancellation terms before committing — standard due diligence for any young DTC health brand.
In full
The 2025 FDA warning letter — the full account
Curex received an FDA warning letter dated September 9, 2025. It is the single item most likely to surface when someone asks whether Curex can be trusted, so rather than leave it to a one-line mention, here is the whole of it.
Marketing language for compounded GLP-1 medications
The letter was part of an industry-wide FDA action that reached more than 50 companies compounding or selling GLP-1 weight-loss medications. The agency objected to wording that could lead a reader to believe a compounded preparation is a generic or equivalent version of an FDA-approved drug such as Wegovy or Ozempic. The objection was to how the products were described.
Not about allergy care, and not an enforcement action
It made no finding about sublingual immunotherapy, allergy drops, or allergen extracts. It was not a product recall, not a safety finding about any medication, not an action against the clinical practice, and not a lawsuit. If you are weighing Curex for allergy treatment, this letter does not bear on that decision.
Corrected — and the correction is checkable
Curex states that it addressed the FDA’s concerns and corrected the marketing language. That is not something you have to take on faith: Curex’s current materials state that compounded GLP-1 medications have not been approved by the FDA and are explicitly not the same as branded drugs like Wegovy or Ozempic — the opposite of the wording the letter objected to.
Fit
Who it fits — and who should see someone in person
Online sublingual immunotherapy suits people with environmental allergic rhinitis who are appropriate candidates. If you have a history of anaphylaxis, poorly controlled or severe asthma, or suspected food or drug allergy, you should be evaluated by an allergist in person — a responsible service will tell you so rather than treat everyone the same. See our honest guide to when you need an allergist in person.
❓Frequently Asked Questions
Yes. Curex is a real US telehealth company founded in 2019, based in New York, that provides at-home sublingual immunotherapy (allergy drops) for environmental allergies, using licensed clinicians and at-home allergen testing. The underlying treatment — sublingual immunotherapy — is a recognized, evidence-based approach.
Custom multi-allergen sublingual drops are prescribed off-label, which is legal and routine in US medicine — the allergen extracts are FDA-regulated, but the personalized compounded mixture is not a fixed FDA-approved product. Off-label does not mean unproven or unsafe; it also does not mean the FDA has evaluated that specific mixture. Only single-source sublingual tablets (grass, ragweed, dust mite) are FDA-approved.
In September 2025 the FDA sent Curex a warning letter as part of an industry-wide action that reached more than 50 companies compounding or selling GLP-1 weight-loss medications. It concerned marketing language for compounded semaglutide and tirzepatide — specifically wording that could lead a reader to believe a compounded preparation is a generic or equivalent version of an FDA-approved drug such as Wegovy or Ozempic. It was not a product recall, not a safety finding about any medication, and not a lawsuit. Curex states that it addressed the agency’s concerns and corrected the language, and that correction is visible today: Curex’s current materials say plainly that compounded GLP-1 medications are not FDA-approved and are not the same as Wegovy or Ozempic.
No. The September 2025 warning letter addressed marketing language for compounded GLP-1 weight-loss medications, a separate product line. It made no finding about sublingual immunotherapy, allergy drops, allergen extracts, or the safety of allergy treatment, and it did not restrict the allergy service in any way. Anyone evaluating Curex for allergy care should weigh the allergy evidence on its own terms.
As of this writing, the New York telehealth entity (Curex, Inc.) is not BBB accredited and carries a BBB rating of C. As with any young direct-to-consumer health company, it is reasonable to read recent customer reviews and understand the billing and cancellation terms before subscribing.
Sublingual immunotherapy is supported by a Cochrane review of 60 randomized, placebo-controlled trials showing reduced allergic-rhinitis symptoms and medication use. A 2026 real-world study of 2,897 patients on telemedicine-delivered sublingual immunotherapy reported symptom improvement rising over time, high adherence, and no anaphylaxis — an observational study, so it shows patients improved and stayed on treatment rather than proving superiority over other routes.
Anyone with a history of anaphylaxis, poorly controlled or severe asthma, or suspected food or drug allergy should be evaluated by an allergist in person. Online sublingual immunotherapy is best suited to environmental (aeroallergen) allergic rhinitis in appropriate candidates.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.